Faeth Therapeutics, Inc.(FTH)

$40.05—Stale · unknown old

Chart

Faeth Therapeutics, Inc.(FTH)

NASDAQ • Last print unknown ago

$40.05—Stale · unknown old

Chart Studio

FTH(FTH)

FTH

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.66

Nov 13, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus

Buy

5 analysts·Limited coverage

Score

5 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

5100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$50.00

+24.8%

Consensus

$56.50

+41.1%

Bull

$60.00

+49.8%

12-Month Target Range5 analysts

$50.00$56.50$60.00

Current $40.05Consensus

Current Price

$40.05

Upside to Consensus

$16.45

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev—

EPS—

FY2028

Rev—

EPS—

FY2029

Rev-31.62%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	—	—	$6M	$4M	$31M
Low	—	—	$6M	$4M	$31M
High	—	—	$6M	$4M	$31M
EBITDA Avg	—	—	$-6M	$-5M	$-5M
Low	—	—	$-8M	$-5M	$-5M
High	—	—	$-3M	$-5M	$-5M
EBIT Avg	—	—	$-6M	$-5M	$-5M
Low	—	—	$-8M	$-5M	$-5M
High	—	—	$-3M	$-5M	$-5M
Net Income Avg	$-19M	$-5M	$-6M	$-5M	$-5M
Low	$-20M	$-6M	$-8M	$-5M	$-5M
High	$-17M	$-3M	$-3M	$-5M	$-5M
EPS Avg	$-14.99	$-3.19	$-3.84	$-4.07	$-3.94
Low	$-15.94	$-4.79	$-6.31	$-4.07	$-3.94
High	$-13.62	$-2.49	$-2.68	$-4.07	$-3.94
Analysts (Rev / EPS)	— / 5	— / 5	8 / 7	6 / 2	6 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBITDA Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
Net Income Avg	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
Low	$-5M	$-5M	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
High	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M	$-4M
EPS Avg	$-0.80	$-0.75	$-0.69	$-0.71	$-0.73	$-0.73	$-0.74	$-0.75
Low	$-0.88	$-0.82	$-0.69	$-0.71	$-0.73	$-0.73	$-0.74	$-0.75
High	$-0.70	$-0.72	$-0.69	$-0.71	$-0.73	$-0.73	$-0.74	$-0.75
Analysts (Rev / EPS)	— / 2	— / 2	— / 1	— / 1	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Aug 21, 2026Needham

Faeth Therapeutics initiated with a Buy at Needham

Target:$56.00

+74.5%from $32.10

Jul 31, 2026Raymond James

Raymond James Starts Faeth Therapeutics (FTH) at Outperform

Target:$56.00

+94.3%from $28.82

Jul 27, 2026Oppenheimer

Faeth Therapeutics initiated with an Outperform at Oppenheimer

Target:$60.00

+105.2%from $29.24

Jun 25, 2026Robert W. Baird

Faeth Therapeutics initiated with an Outperform at Baird

Target:$57.00

+131.0%from $24.67

Jun 22, 2026H.C. Wainwright

Faeth Therapeutics initiated with a Buy at H.C. Wainwright

Target:$60.00

+236.7%from $17.82

May 28, 2026Loop Capital Markets

Lucid Capital Markets Starts Sensei Biotherapeutics (SNSE) at Buy

Target:$50.00

+200.3%from $16.65

May 13, 2024Stephens

Sensei Biotherapeutics initiated with an Overweight at Stephens

Target:$5.00

+218.5%from $1.57

Dec 13, 2022Citigroup

Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $6

Target:$6.00

+244.8%from $1.74

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance